PQ32 is an anti-tumor agent targeting c-MYCPu27 and KRASG-quadruplexes. It hinders the proliferation of tumor cells, arrests the cell cycle at the G2 phase, and induces apoptosis (apoptosis). PQ32 suppresses the expression of c-MYC and KRAS genes. It can inhibit tumor growth in mice and is applicable for research in cancers such as lymphoma, breast cancer, lung cancer, hepatocellular carcinoma, and colorectal cancer.

PQ32 demonstrates antitumor activity against RAJI, CA46, MDA-MB-231, A549, HepG2, HT29, and HEK-293T cell lines with IC50 values of 1.75, 2.68, 1.07, 3.48, 2.72, 1.50, and 4.09 μM, respectively. PQ32 at 1.5 μM for 24 hours can induce cell cycle arrest and apoptosis in MDA-MB-231 cells. Additionally, PQ32 at concentrations ranging from 1.5 to 3 μM over 24 to 72 hours can inhibit the expression of c-MYC and KRAS genes and proteins in MDA-MB-231 cells.

PQ32, when administered at 15 mg/kg through intratumoral injection every two days for a duration of 21 days, effectively inhibits tumor growth in HT29 xenografted nude mice.